EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Suprachoroidal Triamcinolone Injection for the Management of Chronic Uveitis‐Associated Ocular Hypotony

Dan Spiegelman iD, Isabella Song, Erin Sieck iD

Case Reports in Ophthalmological Medicine · 2026-01 · 2026 (1)

DOI: 10.1155/crop/2476023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Case Reports in Ophthalmological Medicine, online erschienen am 27.06.2026. Verfasst von Dan Spiegelman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA, wustl.edu. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study is aimed at describing the use of suprachoroidal triamcinolone injection for the treatment of refractory uveitis‐associated ocular hypotony presumed secondary to ciliary body shutdown.

Methods

We report a case of a 58‐year‐old woman with a 26‐year history of idiopathic, noninfectious bilateral panuveitis complicated by recurrent cystoid macular edema and a steroid‐induced ocular hypertension. After treatment with an intravitreal dexamethasone implant and an Ahmed glaucoma valve, she developed persistent hypotony in the right eye with intraocular pressure (IOP) of 2–4 mmHg despite controlled inflammation. Evaluation with gonioscopy and ultrasound biomicroscopy revealed no cyclodialysis cleft or cyclitic membranes. Prior treatments, including topical steroids, repeat dexamethasone implant, Ahmed valve revision, and serial anterior chamber viscoelastic injections, produced only transient improvement. Suprachoroidal triamcinolone (40 mg) was administered.

Results

Before injection, IOP ranged from 2 to 6 mmHg. Following treatment, IOP remained ≥ 6 mmHg for approximately 2 months. Best corrected visual acuity improved from 20/80 to 20/50, and additional viscoelastic injections were not required during this period. Numerical hypotony recurred 8 months later.

Conclusion

Suprachoroidal triamcinolone may represent a targeted treatment for refractory uveitis‐associated hypotony when ciliary body dysfunction is suspected and other steroid delivery routes are limited. Further study is needed to evaluate durability and broader applicability.

Schlagwörter

Stichwörter der Autor:innen

ocular hypotonysteroid therapysuprachoroidal triamcinoloneuveitis

Autor:innen und Institutionen

  • Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA, wustl.edu.
  • John F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University in St. Louis, St. Louis, Missouri, USA, wustl.edu.

ORCID-Profile: Dan Spiegelman, Erin Sieck

Zitieren

APA

Spiegelman, D., Song, I., & Sieck, E. (2026). Suprachoroidal Triamcinolone Injection for the Management of Chronic Uveitis‐Associated Ocular Hypotony. Case Reports in Ophthalmological Medicine, 2026(1). https://doi.org/10.1155/crop/2476023

Vancouver

Spiegelman D, Song I, Sieck E. Suprachoroidal Triamcinolone Injection for the Management of Chronic Uveitis‐Associated Ocular Hypotony. Case Reports in Ophthalmological Medicine. 2026;2026(1). doi:10.1155/crop/2476023

BibTeX
@article{Spiegelman2026,
  author = {Spiegelman, Dan and Song, Isabella and Sieck, Erin},
  title = {Suprachoroidal Triamcinolone Injection for the Management of Chronic Uveitis‐Associated Ocular Hypotony},
  journal = {Case Reports in Ophthalmological Medicine},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crop/2476023}
}
Kostenlos starten →